{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:05:46Z","timestamp":1783688746723,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.transci.2019.07.002","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T11:32:39Z","timestamp":1562671959000},"page":"102587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of plasma exchange using a double viral inactivated and prion reduced solvent\/detergent fresh frozen plasma for the treatment of thrombotic microangiopathy: The first French experience in a single center"],"prefix":"10.1016","volume":"59","author":[{"given":"Pascale","family":"Poullin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Delmotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gensollen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2019.07.002_bib0005","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.transci.2019.07.002_bib0010","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1056\/NEJMcp053024","article-title":"Thrombotic thrombocytopenic purpura","volume":"354","author":"George","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2019.07.002_bib0015","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic microangiopathies","volume":"347","author":"Moake","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2019.07.002_bib0020","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"Von Willebrand factor\u2013cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic\u2013uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2019.07.002_bib0025","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor\u2013cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2019.07.002_bib0030","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2019.07.002_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(16)30018-7","article-title":"Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy","volume":"3","author":"Mariotte","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.transci.2019.07.002_bib0040","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2019.07.002_bib0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"for HUS International","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2019.07.002_bib0050","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","article-title":"Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome","volume":"24","author":"The European Paediatric Study Group for HUS","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2019.07.002_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/4860284","article-title":"Quality assessment of established and emerging blood components for transfusion","volume":"2016","author":"Acker","year":"2016","journal-title":"J Blood Transfus"},{"key":"10.1016\/j.transci.2019.07.002_bib0060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1423-0410.2009.01190.x","article-title":"Biochemical quality of the pharmaceutically licensed plasma OctaplasLG \u00ae after implementation of a novel prion protein (PrP Sc) removal technology and reduction of the solvent\/detergent (S\/D) process time","volume":"97","author":"Heger","year":"2009","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2019.07.002_bib0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/rth2.12160","article-title":"Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine","volume":"3","author":"Coppo","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.transci.2019.07.002_bib0070","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.tracli.2018.07.007","article-title":"Plasma for direct therapeutic use, for today and tomorrow: a short critical overview","volume":"25","author":"Garraud","year":"2018","journal-title":"Transfus Clin Biol J Soc Francaise Transfus Sang"},{"key":"10.1016\/j.transci.2019.07.002_bib0075","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1423-0410.2010.01346.x","article-title":"The effect of prion reduction in solvent\/detergent-treated plasma on haemostatic variables","volume":"99","author":"Lawrie","year":"2010","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2019.07.002_bib0080","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.transci.2017.11.023","article-title":"Are all therapeutic plasma preparations the same: is it worth assessing them in clinical trials?","volume":"56","author":"Garraud","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2019.07.002_bib0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2008.07292.x","article-title":"Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study","volume":"143","author":"del R\u00edo-Garma","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2019.07.002_bib0090","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/trf.13229","article-title":"Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study: THERAPEUTIC PLASMA AND TTP OUTCOME","volume":"55","author":"Toussaint-Hacquard","year":"2015","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.transci.2019.07.002_bib0095","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/vox.12663","article-title":"Characterization of efficacy and safety of pathogen inactivated and quarantine plasma in routine use for treatment of acquired immune thrombotic thrombocytopenic purpura","volume":"113","author":"Herbrecht","year":"2018","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2019.07.002_bib0100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.tracli.2017.10.002","article-title":"Amotosalen-inactivated plasma is as equally well tolerated as quarantine plasma in patients undergoing large volume therapeutic plasma exchange","volume":"25","author":"Guignier","year":"2018","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.transci.2019.07.002_bib0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/trf.13877","volume":"57","author":"Vendramin","year":"2017","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.transci.2019.07.002_bib0110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2019.07.002_bib0115","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1537-2995.2003.00336.x","article-title":"Complications of plasma exchange in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a study of 78 additional patients","volume":"43","author":"McMinn","year":"2003","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.transci.2019.07.002_bib0120","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood-2008-08-175323","article-title":"Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program","volume":"113","author":"Pulsipher","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.transci.2019.07.002_bib0125","first-page":"373","article-title":"Prophylactic low dose continuous calcium infusion during peripheral blood stem cell (PBSC) collections to reduce citrate related toxicity","volume":"54","author":"Hegde","year":"2016","journal-title":"Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis"},{"key":"10.1016\/j.transci.2019.07.002_bib0130","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.transci.2018.02.005","article-title":"Solvent-detergent plasma for the treatment of thrombotic microangiopathies: a Canadian tertiary care centre experience","volume":"57","author":"Lee","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2019.07.002_bib0135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/vox.12090","article-title":"Characterization of the complications associated with plasma exchange for thrombotic thrombocytopaenic purpura and related thrombotic microangiopathic anaemias: a single institution experience","volume":"106","author":"McGuckin","year":"2014","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2019.07.002_bib0140","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/01.mbc.0000061298.28953.7d","article-title":"Coagulation factor content of solvent\/detergent plasma compared with fresh frozen plasma","volume":"14","author":"Doyle","year":"2003","journal-title":"Blood Coagul Fibrinolysis Int J Haemost Thromb"},{"key":"10.1016\/j.transci.2019.07.002_bib0145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.0958-7578.2004.00478.x","article-title":"Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura","volume":"14","author":"Yarranton","year":"2004","journal-title":"Transfus Med Oxf Engl"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050219301181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050219301181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:52:41Z","timestamp":1761468761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050219301181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1473050219301181"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2019.07.002","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of plasma exchange using a double viral inactivated and prion reduced solvent\/detergent fresh frozen plasma for the treatment of thrombotic microangiopathy: The first French experience in a single center","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2019.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102587"}}